The BioPharm Brief: CAR-T Progress, ADC Momentum, Biosimilar Expansion

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today we're looking at three stories that highlight advances in cell therapy, targeted oncology treatments, and biosimilar medicines.

First, Imviva Biotech reported encouraging data for its investigational allogeneic CAR-T therapy CTD402 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. Data presented at the European Hematology Association Congress showed an overall response rate of nearly 86% in adults and an 80% complete remission rate in pediatric patients. The findings add to growing interest in off-the-shelf CAR-T therapies, which could help eliminate manufacturing delays associated with patient-specific treatments.

In antibody-drug conjugate news, Immunome announced that the first patient has been dosed in a Phase 1 trial evaluating IM-1617, a potential first-in-class ADC for advanced solid tumors. The investigational therapy combines a tumor-targeting antibody with the company's proprietary topoisomerase I inhibitor payload and is being evaluated in patients with colorectal cancer, non-small cell lung cancer, breast cancer, and other advanced solid tumors. The milestone marks another step forward in the rapidly expanding ADC field.

Finally, the FDA expanded the label of a tocilizumab biosimilar to include cytokine release syndrome and pediatric COVID-19 indications. The approval broadens patient access to an important immunology therapy while underscoring the growing role biosimilars continue to play in reducing treatment costs and expanding healthcare access.

Taken together, today's stories reflect three major themes shaping biopharma: increasing momentum for off-the-shelf cell therapies, continued investment in next-generation targeted oncology platforms, and expanding regulatory support for biosimilar adoption.

That's all for today's BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• Imviva reported strong response rates for its allogeneic CAR-T therapy CTD402 in relapsed or refractory T-ALL/LBL.
  
• Immunome dosed the first patient in a Phase 1 trial of its potential first-in-class ADC IM-1617.
  
• The FDA expanded indications for a tocilizumab biosimilar, increasing patient access to treatment.